Board of Trustees

Board of Trustees

The GRC Board of Trustees is comprised of 15 distinguished scientists who govern the activities of the organization.  The board collaborates with the GRC Conference Evaluation Committee to evaluate the scientific quality of existing conferences and to approve proposals for new conferences.  Twelve members of the board are elected, two are appointed, and one is a standing member.  The President and CEO also serves as an ex officio member of the board.  New board members are identified by the Nominating Committee, and elected by the GRC Council to serve six-year terms.
  

Member List:

David J. Glass
Chair
Regeneron Pharmaceuticals
Term: November 2016-2022
David J. Glass is the Vice President of Research, Aging & Age-Related Disorders at Regeneron Pharmaceuticals and the Director of Regeneron’s Postdoctoral program there. He’s an MD, and did his postdoctoral training at Columbia University. In 1991, he joined Regeneron Pharmaceuticals, Inc., where he became Vice President of the Muscle Group. Prior to his return to Regeneron in 2019, he served as the Executive Director and Head of the Aging Group at the Novartis Institutes for Biomedical Research for 14 years. During his time at Novartis, David founded a Muscle Group that has brought three novel pharmaceuticals to clinical trials, one of which has been declared a "breakthrough therapy" by the FDA. In 2015 he started a new group to focus on Aging-related signaling pathways, to treat age related disease. In addition, David is interested in increasing education related to the correct design of experiments. He started a course at Harvard Medical School, "Experimental Design for Biologists" and wrote a book of that title. David has attended many Gordon Research Conferences. He recognizes the great importance of high-quality research meetings. He states, "The GRC conferences are important to alert scientists to the latest highlights in their fields. They should be open to new scientists and new ideas. It is extremely important to have a forum for the free exchange of the latest scientific data. These conferences should also help to promote the best methods in science, and to challenge entrenched dogma with improved methods and new findings. Future conferences should strive to bring together scientists who in the past have not interacted at meetings, allowing for cross-fertilization of disciplines and ideas. Also new fields and technologies should be well-represented. It’s also very important to promote pure basic research, since one can never predict from where the next breakthrough will emerge". As an industry scientist, David still greatly appreciates pure basic research, in addition to the importance of translating important findings to human disease.
Frances H. Arnold
Vice Chair
California Institute of Technology
Term: November 2017-2023
Frances Arnold is the Dick and Barbara Dickinson Professor of Chemical Engineering and Biochemistry at the California Institute of Technology. After completing her Ph.D. in Chemical Engineering at the University of California, Berkeley in 1985, she carried out postdoctoral work in Biophysical Chemistry in the laboratory of Dr. Ignacio Tinoco. She joined the Caltech faculty in 1987. Her research is in protein design and engineering and she is best known for her pioneering work in directed enzyme evolution. Arnold’s laboratory has pursued a fundamental understanding of protein evolution as well as applications that include therapeutic proteins, sensors for brain imaging, biocatalysts for chemical synthesis, and catalysts for alternative energy. She has more than 200 refereed publications and more than 30 issued patents. Frances serves on the Advisory Board for the Packard Foundation’s Fellows Program and the President’s Advisory Council for the King Abdullah University of Science and Technology. Her many awards and honors include a Nobel Prize in Chemistry in 2018. GRC Cruickshank Lecturer in 2005. Arnold is the only woman to have been elected to all three US National Academies: the National Academy of Engineering, the Institute of Medicine, and the National Academy of Science. She is also a member of the American Academy of Arts and Sciences and received the 2011 Charles Stark Draper Prize of the National Academy of Engineering. Arnold states, "The GRC plays such an important role in introducing young people to their scientific communities, maintaining vibrant discussions in established fields, and in the scientific development of new fields. Future conferences should recognize these critical roles and support global participation".
Donald Hilvert
Past Chair
ETH Zurich
Term: November 2015-2021
Donald Hilvert is Professor and Chair of the Department of Chemistry and Applied Biosciences at the ETH Zurich, Switzerland. Hilvert obtained his Ph.D. in Chemistry from Columbia University. Following postdoctoral work at Rockefeller University, Hilvert joined the faculty of the Scripps Research Institute in La Jolla, California in 1986. Since October 1997, Hilvert has been Professor in the Laboratory of Organic Chemistry at the ETH Zurich. Hilvert's research program focuses on understanding how enzymes work and evolve and on mimicking the properties of these remarkable catalysts through design. Hilvert's work has been recognized by a number of awards, including the Arthur C. Cope Scholar Award from the American Chemical Society, the Pfizer Award in Enzyme Chemistry, the Protein Society Emil Thomas Kaiser Award, and the Breslow Award for Achievement in Biomimetic Chemistry. Hilvert is an elected Fellow of the American Academy of Arts and Sciences and has also received an honorary doctorate from Uppsala University. In addition to participating in 30 Gordon Research Conferences over the years, Hilvert co-chaired the Bioorganic GRC in 1998 and the Biocatalysis GRC in 2006. Such conferences provide scientists an invaluable forum for discussing topical research developments in their own fields as well as exciting opportunities for reaching across traditional scientific boundaries. Hilvert states, "Although the inclusiveness of GRCs is already admirable, their attractiveness for the international scientific community could still be enhanced and ongoing efforts to engage scientists just starting their careers, as well as those active in non-academic settings, further expanded."
Dennis A. Dougherty
California Institute of Technology
Term: November 2015-2021
Dennis A. Dougherty is the George Grant Hoag Professor of Chemistry and the Norman Davidson Leadership Chair in the Division of Chemistry and Chemical Engineering at the California Institute of Technology. Dougherty received his B.S. from Bucknell University, a Ph.D. from Princeton University, and did postdoctoral work at Yale University. Dougherty is a member of the National Academy of Sciences and has received numerous scientific awards. Dougherty has published over 200 articles and has delivered distinguished lectureships around the world. Dougherty has been recognized with several teaching awards at Caltech, including the Richard Feynman Prize. Dougherty is the co-author, with Professor Eric Anslyn, of the influential textbook, Modern Physical Organic Chemistry. Dougherty's research spans the disciplines from physical organic chemistry to chemical biology to neuroscience. Dougherty introduced the cation-π interaction, a powerful noncovalent binding interaction that is widely employed in both small molecule and macromolecular recognition in biology and chemistry. Dougherty's current research is focused on molecular neurobiology, applying the mindset and tools of physical organic chemistry to the complex proteins of neuroscience. A highlight of this work has been determining the critical role that cation-πinteractions play in establishing the addictive properties of nicotine. Dougherty has attended many Gordon Conferences and chaired the GRC on Ligand Recognition and Molecular Gating in 2004. Dougherty states, "Attending a GRC is always enlightening and stimulating, but more than once I have attended a meeting in an area that was relatively new to me, because my research was heading in a new direction. I learned a great deal and made lasting connections with leaders in the field. Going forward, this potential for (re)invigorating a research program should be encouraged by continuing to ensure strong participation by younger scientists and also, when possible, opening slots to out-of-field researchers, who would provide interesting new perspectives to the meeting and could move a research area in a new direction."
Mark A. Murcko
Relay Therapeutics, Inc.
Term: November 2016-2022
Mark Murcko is a chemist who has contributed to seven marketed drugs and several others currently in mid-stage clinical trials. Murcko was Chair of the 2013 Medicinal Chemistry GRC and co-organizer of the 2008 ACS National Medicinal Chemistry Symposium. He is a co-inventor on 50 issued and pending patents, a co-author or 85 scientific articles (H-index = 50), and has delivered roughly 200 invited lectures. Murcko has attended roughly 30 GRCs and has been an invited speaker at GRCs covering six different disciplines. Murcko is the Chief Scientific Officer of Relay Therapeutics in Cambridge, Massachusetts and is also a Senior Lecturer in the Department of Biological Engineering at MIT. He serves on numerous scientific advisory boards and corporate boards of directors for a diverse range of companies in the biomedical space. Murcko received his PhD from Yale and then worked at Merck Sharpe & Dohme, where he contributed to the discovery of multiple clinical candidates including inhibitors of carbonic anhydrase for the treatment of glaucoma. One of these candidates, dorzolamide, was commercialized in two medicines, Trusopt and Cosopt. Trusopt was the first marketed drug in pharmaceutical history to result from a structure-based drug design program. In 1990, Murcko was a founding scientist of Vertex Pharmaceuticals and rose to be Chief Technology Officer and Chair of the Scientific Advisory Board. Murcko is a co-inventor of the HCV drug Incivek (telaprevir), as well as the HIV drugs Agenerase (amprenavir)and Lexiva (fosamprenavir). He helped to guide the early efforts of Vertex’s cystic fibrosis program that later produced the marketed drugs Kalydeco (ivacaftor) and Orkambi (lumacaftor / ivacaftor). He is a co-inventor of 8 other clinical candidates in multiple disease areas and was responsible for starting many of Vertex's more recent programs that have led to active clinical candidates, notably Vertex’s influenza drug VX-787 currently in phase II, and Vertex’s cancer drug VX-970,currently in Phase I. Murcko states, "The GRC mission statement demonstrates the commitment of the organization to addressing a wide range of critical issues. To further strengthen the pre-eminent role of the GRC, I would focus on a few key strategic questions: (1) How can the global reach of the GRC be extended? (2) How can more interdisciplinary science be encouraged? (3) How can information technologies be used to enhance the value of the Conferences both to the scientific community and the broader population?"
Elsa Reichmanis
Lehigh University
Term: November 2019-2022
Elsa Reichmanis is Professor and Carl Robert Anderson Chair in Chemical Engineering in the Department of Chemical and Biomolecular Engineering at Lehigh University. Prior to joining Lehigh, she was Professor and Pete Silas Chair in Chemical Engineering in the School of Chemical and Biomolecular Engineering at the Georgia Institute of Technology. She started her independent career at Bell Labs where she was Bell Labs Fellow and Director of the Materials Research Department. She received her Ph.D. and BS in Chemistry from Syracuse University. She is a member of the National Academy of Engineering and has received several awards for her work, including the American Chemical Society Award in Applied Polymer Science, the American Chemical Society Award in the Chemistry of Materials, the American Institute of Chemical Engineering Margaret H. Rousseau Pioneer Award for Lifetime Achievement by a Woman Chemical Engineer and the Society of Chemical Industry Perkin Medal. She has also been active in professional societies; she served as 2003 President of the ACS and has participated in many National Research Council activities. Her research, at the interface of chemical engineering, chemistry, materials science, optics, and electronics, spans from fundamental concept to technology development and implementation. Her interests include the chemistry, properties and application of materials technologies for photonic and electronic applications, with particular focus on polymeric and nanostructured materials for advanced technologies. Currently, efforts aim to identify fundamental parameters that will enable sub-nanometer scale dimensional control of organic, polymer and/or hybrid active materials. Reichmanis has attended several Gordon Research Conferences and recognizes the impact these conferences have in abroad range of scientific disciplines. Importantly, they bring scientists from the academic, industrial and government sectors together to discuss the latest discoveries. They also play a significant role in promoting early career investigators. Reichmanis states, "The GRC provides a forum for the open exchange of current scientific results and ideas. They also foster an atmosphere of openness and collaboration among scientists from different disciplines. As science becomes a truly global enterprise, it is important for the GRC to lead in addressing the new challenges and needs of the community".
Albert Cheung Hoi Yu
Neuroscience Research Institute, Peking University
Term: November 2019-2022
Albert Cheung-Hoi Yu is Professor and Vice Director of the Neuroscience Research Institute, at Peking University. He received his PhD in Pharmacology from the University of Saskatchewan, Canada. He then moved to work at UCSF and Stanford University before returning to Hong Kong and Beijing to work in Hong Kong University of Science and Technology and Peking University. His research focus on the functional studies of astrocyte under both physiological and pathological conditions. He has published over 5 books in the field of astrocyte research and over 150 peer-reviewed scientific articles. He is the recipient of the 2004 Hong Kong Award for Industry, 2008 Asian Knowledge Management Award – Leadership and 2009 Asia Pacific Frost & Sullivan Product Differentiation Excellence Award for In-Vitro Diagnostics. He is currently serving as Chairman of Hong Kong Biotechnology Organization, Director of Asia Fund for Cancer Research, Vice President of The Chinese Neuroscience Society, Member of HKSAR Commission on Strategic Development, Chairman of Hong Kong Council for Testing and Certification and Director of Hong Kong Science and Technology Parks Corporation. He is honored to serve on the Board of Trustees of the Gordon Research Conferences and has participated in numerous Gordon Research Conferences. Yu states, "He recognizes the profound impact of GRC conferences in fostering the development of scientific research and offering a crucial platform for young investigators in China to develop into leaders in their research field. He has extensive experience in chairing and organizing over 20 international conferences. Every effort he spent is to accelerate scientific blossom in Hong Kong and China. He looks forward to seeing GRC conferences to grow in Asia and become a cultivation ground for all young scientists in China".
Kristi Anseth
University of Colorado at Boulder
Term: November 2017-2023
Kristi Anseth is a Professor of Chemical and Biological Engineering and Associate Faculty Director of the BioFrontiers Institute at the University of Colorado at Boulder. She currently holds the Tisone Professorship and is a Distinguished Professor. Dr. Anseth came to CU-Boulder after earning her B.S. degree from Purdue University, her Ph.D. degree from the University of Colorado, and completing post-doctoral research at MIT as an NIH fellow. Her research interests lie at the interface between biology and engineering where she designs new biomaterials for applications in drug delivery and regenerative medicine. Dr. Anseth’s research group has published over 350 peer-reviewed manuscripts, and she has trained more than 110 graduate students and postdoctoral associates. She is an elected member of the National Academy of Engineering (2009), the National Academy of Medicine (2009), the National Academy of Sciences (2013), the National Academy of Inventors (2016) and the American Academy of Arts and Sciences (2019). Most recently, she received the L’Oreal-UNESCO for Women in Science Award in the Life Sciences (2020). Dr. Anseth has served on the Board of Directors and as President of the Materials Research Society, the Board of Governors for Acta Materialia, Inc, the NIH Advisory Council for NIBIB, and as Chair of the NAE US Frontiers of Engineering meetings. She has participated in numerous Gordon Research Conferences over the past 20 years, and notes that “At the core of any GRC is exceptional technical programming and a vibrant scientific community. However, scientific exchange is evolving in newfound ways, and GRCs have the opportunity to nucleate activities to better bridge global communities, erase boundaries between research disciplines, and engage the next generation of scholars. While I believe that the core focus should remain on programs and people, GRC forums should continually evolve to maintain their excellence and respond nimbly to new opportunities that encourage engagement, adaptability, and connectivity.”
Cynthia J. Burrows
University of Utah
Term: November 2018-2024
Cynthia J. Burrows is Distinguished Professor and Chair of the Department of Chemistry at the University of Utah where she also holds the Thatcher Presidential Endowed Chair of Biological Chemistry. She is a graduate of the University of Colorado, Boulder (B.A. in Chemistry), and of Cornell University (Ph.D. in Chemistry), and was an NSF-CNRS postdoctoral fellow with Jean-Marie Lehn in Strasbourg, France, before starting her independent career at Stony Brook University. After rising through the ranks at Stony Brook, she moved to the University of Utah in 1995. She is a member of the American Academy of Arts and Sciences and the National Academy of Sciences. Her research has roots in physical organic chemistry and now focuses on nucleic acid chemistry, notably the impact of free radicals generated by oxidative stress on formation of modified bases in DNA and RNA, the biochemical effects of DNA lesions, and the impact of base modifications on gene expression. She first chaired a GRC in 1993 (Physical Organic) when her triplets were 10 months old; subsequently she has chaired the Nucleic Acids GRC (2007) and the Nucleosides, Nucleotides, and Oligonucleotides GRC (2017). Burrows states, “Gordon Research Conferences are an excellent mechanism for building communities that support career advancement for junior and senior scientists alike. GRCs in recent years have helped promote diversity and inclusion among their participants. Future GRCs might also help build collaborative research teams, given that more federal funding is trending toward consortia of complementary scientists tackling big questions. This could be approached through strategic invitations to participants and by scheduling discussion groups or poster sessions that address big ideas in cross-disciplinary fields.”
Viola Vogel
ETH Zurich
Term: November 2018-2024
Viola Vogel studied Physics and Biology in Frankfurt, at the Max-Planck Institute for Biophysical Chemistry in Göttingen and in Berkeley before starting her academic career in the Department of Bioengineering at the University of Washington (1991). In Seattle, she was the Founding Director of the Center for Nanotechnology at the University of Washington (1997-2003). When moving to ETH Zurich in 2004, she initially joined the Department of Materials. She is now heading the Laboratory of Applied Mechanobiology was the Founding Director of the new Institute of Translational Medicine. She pioneered the rapidly growing field of Mechanobiology and its medical applications as she discovered many structural mechanisms how mechanical forces can turn proteins into mechano-chemical switches. Such mechanisms are exploited by bacteria, as well as by mammalian cells and tissues to sense and respond to mechanical forces, and if abnormal, can cause various diseases. Her research was recognized by major awards, including an ERC Advanced Grant (2008-13), the International Solvay Chair in Chemistry Brussels 2012, an Honorary Degree Doctor of Philosophy from Tampere University, Finland 2012 and an Einstein Fellowship at Charité, Berlin 2018-21. She also served on various international advisory boards in the fields of nanotechnology and bioengineering, including on the White House panel that finalized the US National Nanotechnology Initiative under the Clinton administration (1999), on the World Economic Forum Global Agenda Council in Nanotechnology (2014-2016), as well as for the Max-Planck Society, A*STAR Singapore and the Wyss Institute, Boston. Vogel states, “Do you remember your first Gordon Research Conferences which introduced you to the pioneers of the field, listening carefully to what they have to say? Preserving this personal character while introducing new cutting-edge scientific directions is increasingly important in a rapidly growing community of scientists that conduct prime research around the globe.”
David Weitz
Harvard University
Term: November 2019-2025
David Weitz received a PhD in physics from Harvard, and then worked at Exxon Research and Engineering for nearly 18 years. He became a professor of physics at the University of Pennsylvania and moved to Harvard as professor of physics and applied physics at the end of the last millennium. He leads a group studying soft matter physics, biophysics, microfluidics, biotechnology and flow in porous media. Weitz has trained 75 graduate students and 170 post docs. He has published over 700 papers and has been granted over 40 patents with another 30 being processed. More than 20 companies have spun out from his lab and these have created over 500 new jobs for scientists and engineers. He has been director of Harvard’s NSF-funded Materials Research Science and Engineering Center for nearly 20 years and is a core member of the Wyss Institute for Biomedical Engineering. He co-created ‘Science and Cooking: from Haute Cuisine to Soft Matter Science,’ which brings world-class chefs to the classroom to help teach a course on soft matter science themed on cooking. It has become one of the most popular classes at Harvard, and the YouTube videos have garnered more than 4M hits. The EdX online class has had over 300,000 students. Weitz is a member of the National Academy of Science, the National Academy of Engineering and the American Academy of Arts and Sciences. Weitz has attended about 45 GRCs and co-chaired the 2009 Soft Matter GRC.  Weitz states, “GRCs are among the most venerable and outstanding conferences with an ideal format to encourage interactions among scientists. To retain their health, they must continue to grow to reflect new and changing science, particularly at the boundaries of disciplines.”
Monica Olvera de la Cruz
Northwestern University
Term: November 2019-2025
Monica Olvera de la Cruz is the Lawyer Taylor Professor of Materials Science and Engineering, Professor of Chemistry, of Physics and Astonomy and of Chemical and Biological Engineering and Director of the Center for Computation and Theory of Soft Materials at Northwestern University. She is a versatile scientist who has developed theoretical models to determine the thermodynamics, statistics and dynamics of soft materials including molecular electrolytes, hydrogels, membranes and multicomponent solutions of complex macromolecules such as functionalized nanoparticles, polymers and biomolecules. She obtained her BA in Physics from the National University of Mexico (UNAM), and her Ph.D. in Physics from Cambridge University, UK. From 1995-97 she was a Staff Scientist in the Service de Chimie Moleculaire, Commissariat a l’Energie Atomique (CEA), Saclay, France. She is a member of the National Academy of Sciences (NAS), the American Academy of Arts and Sciences and a Fellow of the American Physical Society (APS). She has been the recipient of multiple awards and prizes including the 2017 American Physical Society Polymer Physics Prize, a 2010 National Security Science and Engineering Fellowship (DoD) and the 2007 Cozzarelli Prize in Applied Sciences (NAS). She has advised and chaired various federal funding agencies and National Research Council committees, and is currently a member of the US Department of Energy Basic Energy Sciences Advisory Committee and Senior Editor of ACS Central Sciences. She has attended multiple GRCs and has published over 300 scientific papers. Olvera de la Cruz states, “GRC cultivates an environment conducive to interdisciplinary learning and scientific discovery by fostering interactions among senior and junior academicians, scientists at government laboratories and industrial associates from all over the globe. In modern times, information theory and computer science are crucial components of scientific and engineering research. GRC should continue to nucleate scientific breakthroughs by developing conferences at the intersection of information, life and physical sciences.”
Sam Gellman
University of Wisconsin - Madison
Term: November 2020-2026
Sam Gellman is the Ralph F. Hirschmann Professor of Chemistry and a Vilas Research Professor at the University of Wisconsin - Madison.  He earned his A.B. from Harvard University in 1981 and his Ph.D. from Columbia University, under Ronald Breslow, in 1986.  After an NIH post-doctoral fellowship at the California Institute of Technology with Peter Dervan, Gellman joined the faculty at the University of Wisconsin - Madison in 1987.  Major interests in Gellman's program involve polypeptide structure and function in diverse forms and settings.  Specific topics include fundamental studies of non-covalent interactions, elucidation of the origins of peptide and protein folding preferences, development and application of unnatural peptidic oligomers that display protein-like conformational behavior and activities ("foldamers"), creation of new amphiphiles for membrane protein manipulation, and development of biologically active polymers. Gellman has mentored 71 students to the Ph.D., along with many others who have earned an M.S. or conducted research at the undergraduate level.  He has enjoyed introducing thousands of UW-Madison undergraduates to the pleasures of organic chemistry in the classroom. Gellman is a Fellow of the American Academy of Arts & Sciences and a Member of the U.S. National Academy of Science.  Gellman has attended Gordon Research Conferences in several areas; he was co-chair of the 2010 Peptides GRC. Gellman believes that Gordon Research Conferences have long set the standard for vibrant and effective meetings that encourage all productive modes of scholarly exchange. "Going forward, GRC should harness the well-deserved prominence throughout the scientific community to complement the established record of responding to new scientific and geographic opportunities by seeking new approaches to bringing historically underrepresented voices into high-level scientific conversations."
Randy Schekman
University of California, Berkeley
Term: November 2020-2026
Randy Schekman is a Professor in the Department of Molecular and Cell Biology, University of California, Berkeley, and an Investigator of the Howard Hughes Medical Institute.  He studied the enzymology of DNA replication as a graduate student with Arthur Kornberg at Stanford University.  His current interest in cellular membranes developed during a postdoctoral period with S. J. Singer at the University of California, San Diego.  Schekman’s laboratory investigates the mechanism of membrane protein traffic in the secretory pathway in eukaryotic cells. In recent years his lab has turned to aspects of vesicular traffic in human cells, most recently on the biogenesis and sorting of small RNAs into extracellular vesicles. Among his awards are the Gairdner International Award, the Albert Lasker Award in Basic Medical Research and the Nobel Prize in Physiology or Medicine, which he shared with James Rothman and Thomas Südhof.  From 2006 - 2011 he served as Editor-in-Chief of the Proceedings of the NAS.  In 2011, he founded and until 2019 served as the Editor-in-Chief of the Open Access journal, eLife, sponsored by the HHMI, Wellcome Trust and the Max Planck Society.  Beginning in 2018, Schekman assumed a leadership role in an effort to identify and support basic research on the mechanisms of Parkinson’s Disease initiation and progression. Schekman has participated in and organized GRC’s since 1979 and was a member of the group that initiated the enormously successful GRC on Molecular Membrane Biology, a meeting that he chaired in 1987 and has been invited to speak in ever since.  He believes that “GRC has and continues to play an essential role in the dissemination of the most important cutting-edge results and approaches in all of science.  Going forward, the impact of this forum should be extended to include the virtual participation of an extended audience to join those who assemble at the usual venues.”
Sudip Parikh
American Association for the Advancement of Science
Term: Standing Appointment
Sudip Parikh is the Chief Executive Officer and Executive Publisher of the Science family of journals at the American Association for the Advancement of Science (AAAS).  He received his B.S. in Materials Applied Science from the University of North Carolina at Chapel Hill and was awarded a National Science Foundation Graduate Research Fellowship while earning his Ph.D. in macromolecular structure and chemistry from the Scripps Research Institute in La Jolla, California. Following a Presidential Management Fellowship at the U.S. National Institutes of Health, he served for 9 years as science advisor and professional staff to the United States Senate Appropriations Committee where he was responsible for negotiating budgets for the NIH, CDC, and other science agencies. He then served as general manager of the Health and Consumer Solutions business unit and vice president at Battelle where he led a team of over 500 scientific, technical, and computing experts performing basic and applied research, developing medicines and healthcare devices, and creating advanced analytics and AI applications to improve human health. Immediately prior to joining AAAS, he was senior vice president and managing director at DIA Global, a neutral, multidisciplinary organization bringing together regulators, industry, academia, patients, and others interested in healthcare product development. At AAAS, with a mission to advance science and serve society, he has focused on ensuring that Science is the gold-standard of scientific journals, ensure that the U.S. continues to be a leader in the global culture of science, and address issues of diversity, equity, and inclusion in the scientific enterprise. Parikh states, “Over the decades, the GRC forum has launched thousands of scientific collaborations that have led to key advances. The challenge and opportunity for the GRC is to maintain the intimacy and informal nature of these gatherings while operating at a global scale and with appropriate diversity.”

Contact Us

Call Us:
401-783-4011

Monday - Friday 
8:30 am - 4:30 pm ET



  • Check Your Registration
    Find out about your upcoming GRC meetings.

  • GRC Venues
    Everything you need to know about our venues when planning your trip.

  • FAQs
    Instant answers to common questions.

You have no notifications